updates, always updates, page-20

I think anyone trying to read negative into ACL attending this conference is jumping at shadows, we've been at a fair few of them:

Rodman & Renshaw Conference (New York) - Sept 09
JPM Securities Conference (New York) - Sept 10
AusBiotech - Oct 10
JP Morgan Conference (San Fransisco) - Jan 11
and now,
Cowen Healthcare Conference (Boston)

We have all seen that behind the scene Pete and co have been busy signing up deals with some major Pharma's with respect to the VAST Platform, how does everyone think that these deals come about, it certainly wasn't by staying at home and not getting out there telling the world what ACL has!!

We are going into phase 3 trials for HA-Irinotecan and will be more than covered here with Fonda earnings. But as far as getting HA-I to market, obviously upon successful phase 3, we will need commercial manufacturing, distribution channels and marketing, we can either go it alone and get it to market ourselves or we can partner with Large Pharma, the choice is ours but in 2/3 years time one way or the other would have to be established, negotiated imo.

So away we go to the Conferences, where Investors are looking for opportunity, I think ACL is offering great opportunity for the right partner/deal.